BMS and Acceleron’s Reblozyl (Luspatercept) Receives Health Canada Approval for Adult Patients With Myelodysplastic Syndromes

February 17, 2021 Auto Bot Adult, approval, Health Canada, patients, receives, regulatory 0

Shots:

  • The approval is based on P-III MEDALIST study involves assessing ReblozyL vs PBO in a ratio (2:1) in adult patients with very low- to intermediate-risk MDS-RS requiring regular RBC transfusions (>2 RBC units/ 8 wks)
  • The results showed transfusion independence for 8 wks or longer during the first 24 wks (38% vs. 13%)
  • Reblozyl (luspatercept) is the 1st and only erythroid maturation agent approved in the US, EU and Canada for the treatment of anemia in certain blood disorders and helps to regulate late-stage RBC maturation to potentially reduce the need for RBC transfusions

Click here ­to­ read full press release/ article | Ref: Acceleron | Image: BMS

The post BMS and Acceleron’s Reblozyl (Luspatercept) Receives Health Canada Approval for Adult Patients With Myelodysplastic Syndromes first appeared on PharmaShots.